Information Provided By: 
Fly News Breaks for March 23, 2017
RARE
Mar 23, 2017 | 07:55 EDT
Credit Suisse analyst Kennen MacKay lowered his price target for Ultragenyx to $86 from $90 after the company announced that the Phase 2 trial of triheptanoin for the treatment of tonic clonic/observable and absence seizures in patients with GLUT1-deficiency syndrome did not meet the primary endpoint. Nonetheless, the analyst believes topline GLUT1-DS trial failure still leaves potential for absence seizures, and says he is a buyer on a pullback. He reiterates an Outperform rating on the shares.
News For RARE From the Last 2 Days
